Hepatocellular carcinoma is cancer of
the liver.
·
Abdominal pain or tenderness, especially
in the upper-right part
·
Easy bruising or bleeding
·
Enlarged abdomen
·
Yellow skin or eyes (jaundice)
Hepatocellular carcinoma accounts for
most liver cancers. This type of cancer occurs more often in men
than women. It is usually seen in people ages 50 - 60.
The disease is more common in parts
of Africa and Asia than in North or South America and Europe.
Hepatocellular carcinoma is not the
same as metastatic liver cancer, which starts in another organ
(such as the breast or colon) and spreads to the liver.
In most cases, the cause of liver
cancer is usually scarring of the liver (cirrhosis). Cirrhosis
may be caused by:
·
Alcohol abuse (the most common cause in
the U.S.)
·
Certain autoimmune diseases of the liver
·
Diseases that cause long-term
inflammation of the liver
·
Hepatitis B or
C
virus infection
·
Too much iron in the body (hemochromatosis)
Patients with hepatitis B or C are at
risk for liver cancer, even if they do not have cirrhosis.
Physical examination may show an
enlarged, tender liver.
Tests include:
·
Abdominal CT scan
·
Abdominal ultrasound
·
Liver biopsy
·
Liver enzymes (liver function tests)
·
Liver scan
·
Serum alpha fetoprotein
Some high-risk patients may get
periodic blood tests and ultrasounds to see whether tumors are
developing.
·
Gastrointestinal bleeding
·
Liver failure
·
Spread (metastasis) of the carcinoma
Aggressive surgery or a liver
transplant can successfully treat small or slow-growing tumors
if they are diagnosed early. However, few patients are diagnosed
early.
Chemotherapy and radiation treatments
are not usually effective. However, they may be used to shrink
large tumors so that surgery has a greater chance of success.
Sorafenib toslate (Nexavar), an oral
medicine that blocks tumor growth, is now approved for patients
with advanced hepatocellular carcinoma.
The usual outcome is poor, because
only 10 - 20% of hepatocellular carcinomas can be removed
completely using surgery, however longer survivability and
improved quality of life have been observed in patients
undergoing TACE and RFA. .
If the cancer cannot be completely
removed, the disease is usually fatal within 3 - 6 months.
However, survival can vary, and occasionally people will survive
much longer than 6 months.
Preventing and treating viral
hepatitis may help reduce your risk. Childhood vaccination
against hepatitis B may reduce the risk of liver cancer in the
future.
Avoid drinking excessive amounts of
alcohol. Certain patients may benefit from screening for
hemochromatosis.
If you have chronic hepatitis or
known cirrhosis, periodic screening with liver ultrasound or
measurement of blood alpha fetoprotein levels may help detect
this cancer early.